Local delivery of RhoA siRNA by PgP nanocarrier reduces inflammatory response and improves neuronal cell survival in a rat TBI model

Traumatic brain injury (TBI) is a major cause of death and disability. This study explores a new way to reduce the damage that occurs after a TBI by using tiny particles called nanocarriers to deliver a special molecule (siRNA) that targets a specific protein (RhoA) involved in inflammation and cell death. The researchers used a rat model of TBI and injected the nanocarriers containing the siRNA directly into the injured brain tissue. They found that this treatment reduced inflammation, decreased the size of the brain lesion, and improved the survival of brain cells. These findings suggest that using nanocarriers to deliver siRNA targeting RhoA could be a promising new approach to treat TBI and reduce the long-term consequences of this type of injury.

• 1
  PgP/siRhoA nanoplexes efficiently knockdown RhoA expression in the injured brain tissue, both at the mRNA and protein levels.
• 2
  Treatment with PgP/siRhoA nanoplexes resulted in a significant reduction in lesion volume compared to untreated TBI animals.
• 3
  PgP/siRhoA nanoplex treatment significantly decreased cellular apoptosis and improved neuron cell survival in the ipsilateral cortex.